<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209975</url>
  </required_header>
  <id_info>
    <org_study_id>SLT-blood flow study</org_study_id>
    <nct_id>NCT01209975</nct_id>
  </id_info>
  <brief_title>Retinal Vascular Reactivity in Subjects With Newly Diagnosed Glaucoma Before and After Selective Laser Trabeculoplasty</brief_title>
  <official_title>Retinal Vascular Reactivity in Response to Isoxic Hypercapnia in Subjects With Newly Diagnosed Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess retinal blood flow and vascular reactivity in patients
      with newly diagnosed primary open angle glaucoma pre- and post-primary Selective Laser
      Trabeculoplasty(SLT). Canon Laser Blood Flowmeter will be used for the assessment of retinal
      blood flow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We previously found that vascular reactivity improved after short term treatment with
      dorzolamide drops. It is not clear whether this improvement was a direct effect of the
      medication or secondary effect of the decrease in IOP. We would like to see the change of
      vascular reactivity before and after SLT, which will decrease the intraocular pressure
      without pharmacologic effect.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>blood flow</measure>
    <time_frame>before and two-week after SLT</time_frame>
    <description>The Canon Laser Blood Flowmetry will be used to assess the retinal blood flow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocuclar pressure</measure>
    <time_frame>before and two-week after SLT</time_frame>
    <description>Intraocular pressure (IOP) will be measured by Goldmann applanation tonometry.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>untreated glaucoma patients</arm_group_label>
    <description>We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective Laser Trabeculoplasty</intervention_name>
    <description>Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.</description>
    <arm_group_label>untreated glaucoma patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with untreated primary open angle glaucoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 40-75 years (Male or Female)

          2. Best corrected visual acuity of at least 20/40

          3. No previous treatment for glaucoma

          4. Ametropia less than ±6.0 DS and ±2.5 DC)

          5. Non-smoker

          6. No cardiovascular/respiratory disorders

        Exclusion Criteria:

          1. Past history of diabetes and cerebrovascular accident

          2. Vascular occlusive disease affecting the ocular circulation such as: diabetic
             retinopathy, retinal vein occlusion and retinal artery occlusion

          3. Previous intraocular surgery

          4. Ocular media opacities limiting the use of the imaging tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Hudson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tien Wong</last_name>
    <phone>416-603-5694</phone>
    <email>twong@uhnres.utoronto.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien Wong</last_name>
      <phone>416-603-5694</phone>
      <email>twong@uhnres.utoronto.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Venkataraman ST, Hudson C, Rachmiel R, Buys YM, Markowitz SN, Fisher JA, Trope GE, Flanagan JG. Retinal arteriolar vascular reactivity in untreated and progressive primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2043-50. doi: 10.1167/iovs.09-3630. Epub 2009 Nov 11.</citation>
    <PMID>19907031</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>September 27, 2010</last_update_submitted>
  <last_update_submitted_qc>September 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Chris Hudson</name_title>
    <organization>Department of Ophthalmology and Vision Science</organization>
  </responsible_party>
  <keyword>blood flow</keyword>
  <keyword>glaucoma</keyword>
  <keyword>SLT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

